▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for MERCK Kommanditgesellschaft auf Aktien in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $31.32.
The current consensus among 6 contributing investment analysts is to hold stock in MERCK Kommanditgesellschaft auf Aktien. This rating has held steady since April 2020, when it changed from a Sell consensus rating.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; and an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.